Directly targeting a specific part of the β-catenin protein could provide a new leads in the development of drugs for cancers in which this protein is mutated reports a study in Nature Communications this week. Mutations in β-catenin are important in a range of cancers, including colorectal cancer. Mariann Bienz and co-workers identified a chemical compound that inhibits the interaction of β-catenin with its cofactor BCL9. The compound is found to rely upon a specific part of β-catenin, suggesting that specifically targeting this part of the protein may provide a new strategy to develop direct inhibitors of oncogenic β-catenin. These preliminary findings may aid the development of new anti-cancer drugs.
COVID-19: Assessing instances of long COVID in UK health dataNature Communications
Health technology: New cost-effective smartphone test for middle ear functionCommunications Medicine